Biological age acceleration (OR 1.05, p<0.01) and heart age accelerations of 0-5 and ≥5 years (74% and 141% increased risk) were significantly associated with new-onset stroke in CKM syndrome.
Cohort (n=7,283)
Sí
Do biological age acceleration and heart age acceleration increase the risk of new-onset stroke in individuals with CKM syndrome Stages 0-3?
Biological and heart age accelerations are significantly associated with an increased risk of new-onset stroke in individuals with CKM syndrome Stages 0-3, particularly in men.
Estimación del efecto: OR 1.05
valor p: p=< 0.01
Individuals with cardiovascular-kidney-metabolic (CKM) syndrome face an elevated risk of stroke, yet effective risk stratification indicators remain limited. This prospective study aims to investigate the associations of biological age acceleration (BioAge-gap) and heart age acceleration (HeartAge-gap) with new-onset stroke in individuals with CKM syndrome Stages 0-3, utilizing data from the China Health and Retirement Longitudinal Study (CHARLS) collected between 2015 and 2020. Baseline BioAge-gap and HeartAge-gap were calculated via the Klemera-Doubal method (KDM) and Framingham risk score (FRS), respectively. The primary outcome was self-reported physician-diagnosed stroke identified during the 2018 and 2020 follow-ups. Analysis of 7283 eligible participants aged 45-75 years revealed a positive association between BioAge-gap and new-onset stroke (odds ratio OR = 1.05, p < 0.01). Furthermore, compared to participants with a non-positive HeartAge-gap, those with HeartAge-gaps of 0-5 years and ≥5 years exhibited significantly increased risks of stroke by 74% and 141%, respectively. Subgroup analyses and interaction tests identified a significant gender interaction in the association between HeartAge-gap and stroke, indicating that men with accelerated heart age represent a vulnerable subgroup. Restricted cubic splines (RCSs) confirmed a linear association, and sensitivity analyses validated the robustness of these findings. Integrating these intuitive indicators into clinical practice could facilitate primary stroke prevention and mitigate CKM syndrome progression.
Zhu et al. (Wed,) conducted a cohort in Cardiovascular-kidney-metabolic (CKM) syndrome Stages 0-3 (n=7,283). Biological age acceleration (BioAge-gap) and heart age acceleration (HeartAge-gap) vs. Non-positive HeartAge-gap was evaluated on Self-reported physician-diagnosed stroke (OR 1.05, p=< 0.01). Biological age acceleration (OR 1.05, p<0.01) and heart age accelerations of 0-5 and ≥5 years (74% and 141% increased risk) were significantly associated with new-onset stroke in CKM syndrome.